



Retrospective Analysis of Clinico-Epidemiological Factors in Prostatic Cancer

Thesis

*Submitted for Partial Fulfillment of a Master's Degree in
Clinical Oncology and Nuclear Medicine*

By

Walaa Hatem El Damhogy
M.B, B.Ch,

Under the Supervision of

Prof. Dr. Atef Youssef Riad

*Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

Dr. Mai Mohamed Ezz El Din

*Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

Dr. Nesreen Ahmed Mosalam

*Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَدَانِكَ لَا نَعْلَمُ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Atef Youssef Riad**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Mai Mohamed Ezz El Din**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Nesreen Ahmed Mosalam**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I would like to express my hearty thanks to all **my family** for their support till this work was completed.*

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Walaa Hatem El Damhogy

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	v
Introduction	1
Aim of the Work.....	7
Review of Literature	
📖 Epidemiology and Etiology.....	8
📖 Diagnosis	24
📖 Pathology and Risk Stratification	41
📖 Screening.....	52
📖 Treatment	55
📖 Follow Up	95
Patients and Methods	100
Results	105
Discussion	123
Conclusion and Recommendations	132
Summary	133
References	135
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Nomograms and accounted variables in different stages of prostate cancer	18
Table (2):	Grade groups.....	45
Table (3):	Definitions of American Joint Committee on Cancer TNM Criteria	48
Table (4):	American Joint Committee on Cancer Prognostic Stage Grouping	49
Table (5):	Organizational pre-treatment prostate cancer risk stratification systems	51
Table (6):	Screening Recommendations of Major Societies.....	54
Table (7):	Definitions of active surveillance and watchful waiting	57
Table (8):	Select phase III trials supporting the use of ADT in prostate cancer	78
Table (9):	ECOG Performance Status.....	102
Table (10):	Baseline patients and disease characteristics.....	105
Table (11):	Hormonal treatment in localized and locally advanced PCa	108
Table (12):	Management of localized and locally advanced PCa patients	109
Table (13):	Management of relapsed patients.....	110
Table (14):	First line management among initially metastatic patients.....	111
Table (15):	Second line management	111
Table (16):	Third line management.....	112

List of Tables (cont...)

Table No.	Title	Page No.
Table (17):	Survival in the studied population	113
Table (18):	Survival of non-relapsed localized prostate cancer patients	113
Table (19):	Overall survival correlations with different patient characteristics	115
Table (20):	Correlations between DFS and different patient characteristics were established	119
Table (21):	Correlations between PFS and different patient characteristics were established	122

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Estimated age-standardized rates (World) per 100,000	9
Figure (2):	Axial prostate ultrasound demonstrates a hypoechoic area in the peripheral zone suspicious for prostate cancer	29
Figure (3):	Retroperitoneal lymph node metastasis in 75-year-old man.....	30
Figure (4):	Invasion into adjacent organs	31
Figure (5):	Regions of cancer within the prostate.	32
Figure (6):	Multiparametric MRI.....	33
Figure (7):	Normal peripheral zone with high signal intensity on MR axial T2-weighted image and with a spectral graph demonstrating low choline and high citrate levels.....	35
Figure (8):	Bone scan showing wide spread bone metastasis in prostate cancer patient	36
Figure (9):	Images of a 66-year-old male with biochemically recurrent prostate cancer post-radical prostatectomy.....	37
Figure (10):	Ga-68-BBN PET/CT of a 64-year-old man newly diagnosed with prostate cancer by biopsy	39
Figure (11):	Prostate adenocarcinoma with the most morphological type, acinar type, characterized by back to back proliferation of small to intermediate sized tumor acini with scat to moderate intervening stroma	41
Figure (12):	Gleason pattern	43

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (13):	Prostate cancer local extension.....	47
Figure (14):	Treatment options for localized and metastatic prostate cancer and the sites of action of agents used to treat metastatic castration-resistant prostate cancer	56
Figure (15):	A 3D-CRT external beam radiation plan for treatment of prostate cancer	63
Figure (16):	Patient position and vital component of prostate brachytherapy with transrectal ultrasound guidance.....	68
Figure (17):	Mechanism of action of enzalutamide	89
Figure (18):	Progression free survival.	114
Figure (19):	DFS curve.	114
Figure (20):	Overall survival correlation with performance status.....	116
Figure (21):	Overall survival correlation with M stage.	117
Figure (22):	Overall survival correlation with stage group.....	118
Figure (23):	Disease free survival correlation with levels of performance.	120
Figure (24):	Disease free survival correlation with risk stratification group.....	121

List of Abbreviations

Abb.	Full term
<i>103Pd</i>	<i>Palladium-103</i>
<i>125I</i>	<i>Iodine-125</i>
<i>131Cs</i>	<i>Cesium-131</i>
<i>3-DCRT</i>	<i>3-Dimensional Conformal Radiotherapy</i>
<i>ADT</i>	<i>Androgen Deprivation Therapy</i>
<i>ALK</i>	<i>Alkaline Phosphatase</i>
<i>ASR</i>	<i>Age-standardized rates</i>
<i>AUA</i>	<i>American Urological Association</i>
<i>BcR</i>	<i>Biochemical Recurrence</i>
<i>bPFS</i>	<i>Biochemical Progression-Free Survival</i>
<i>CAB</i>	<i>Combined Androgen Blockade</i>
<i>CAPRA</i>	<i>Cancer of the Prostate Risk Assessment</i>
<i>CAPSURE</i>	<i>Cancer of the Prostate Strategic Urologic Research Endeavour</i>
<i>CBC</i>	<i>Complete Blood Picture</i>
<i>CI</i>	<i>Confidence Interval</i>
<i>CRPC</i>	<i>Castration-Resistant Prostate Cancer</i>
<i>cT</i>	<i>Clinical Tumor</i>
<i>CT</i>	<i>Computerized Tomography</i>
<i>CTC</i>	<i>Common Toxicity Criteria</i>
<i>D</i>	<i>Docetaxel</i>
<i>DCE</i>	<i>Dynamic Contrast Enhancement</i>
<i>DRE</i>	<i>Digital Rectal Examination</i>
<i>DW</i>	<i>Diffusion Weighted</i>
<i>EAU</i>	<i>European Association of Urology</i>
<i>EBRT</i>	<i>External Beam Radiation Therapy</i>
<i>ECOG</i>	<i>Eastern Cooperative Oncology Group</i>
<i>EORTC</i>	<i>European Organization for Research and Treatment of Cancer</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>EPE</i>	<i>Extra-Prostatic Extension</i>
<i>ESMO</i>	<i>European Association of Urology</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>GU</i>	<i>Genitourinary</i>
<i>GUROC</i>	<i>Genitourinary Radiation Oncologists of Canada</i>
<i>GUROC</i>	<i>Genitourinary Radiation Oncologists of Canada</i>
<i>Gy</i>	<i>Gray</i>
<i>HDR</i>	<i>High Dose Radiotherapy</i>
<i>HGPIN</i>	<i>High Grade Prostatic Intraepithelial Neoplasia</i>
<i>HR</i>	<i>Hazard Ratio</i>
<i>HRPC</i>	<i>Hormone-Resistant Prostate Cancer</i>
<i>HVD</i>	<i>High Volume Disease</i>
<i>IADT</i>	<i>Intermittent Androgen Deprivation Therapy</i>
<i>IGRT</i>	<i>Image-Guided Radiation Therapy</i>
<i>IHD</i>	<i>Ischemic Heart Disease</i>
<i>IMRT</i>	<i>Intensity-Modulated Radiotherapy</i>
<i>LDR</i>	<i>Low Dose Radiotherapy</i>
<i>LH-RH</i>	<i>Luteinizing Hormone-Releasing Hormone</i>
<i>mCRPC</i>	<i>Metastatic castrate resistant prostate cancer</i>
<i>mHSPC</i>	<i>Metastatic Hormone-Sensitive Prostate Cancer</i>
<i>MH</i>	<i>Moderate Hypofractionation</i>
<i>MOA</i>	<i>Mechanism of Action</i>
<i>mp-MRI</i>	<i>Multiparametric Magnetic Resonance</i>
<i>MRI</i>	<i>Magnetic Resonance Imaging</i>
<i>MRSI</i>	<i>Magnetic Resonance Spectroscopic Imaging</i>
<i>Ms</i>	<i>Months</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>NCI</i>	<i>National Cancer Institute</i>
<i>NCRP</i>	<i>National Cancer Registry Program</i>
<i>NCCN</i>	<i>National Comprehensive Cancer Network</i>
<i>NICE</i>	<i>National Institute for Health and Clinical Excellence</i>
<i>No</i>	<i>Number</i>
<i>Os</i>	<i>Overall Survival</i>
<i>PCa</i>	<i>Prostatic Cancer</i>
<i>PCSM</i>	<i>Prostatic Cancer Specific Mortality,</i>
<i>Pet</i>	<i>Positron Emission Topography</i>
<i>PFS</i>	<i>Progression Free Survival</i>
<i>PIN</i>	<i>Prostatic Intraepithelial Neoplasia</i>
<i>PLND</i>	<i>Pelvic Lymph Node Dissection</i>
<i>PSA</i>	<i>Prostatic Specific Antigen</i>
<i>PSMA</i>	<i>Prostate- Specific Membrane Antigen</i>
<i>RCTs</i>	<i>Randomized Controlled Trials</i>
<i>RP</i>	<i>Radical Prostatectomy</i>
<i>rPFS</i>	<i>Radiographic Progression-Free Survival</i>
<i>RR</i>	<i>Relative Risk</i>
<i>RT</i>	<i>Radiation Therapy</i>
<i>RTOG</i>	<i>Radiation Therapy Oncology Group</i>
<i>SEARCH</i>	<i>Shared Equal Access Regional Cancer Hospital</i>
<i>SEER</i>	<i>Surveillance, Epidemiology, and End Results</i>
<i>SPCG-4</i>	<i>Scandinavian Prostate Cancer Group Study Number 4</i>
<i>SRT</i>	<i>Salvage Radiotherapy</i>
<i>SVI</i>	<i>Seminal Vesicle Invasion</i>
<i>SWOG</i>	<i>South-Western Oncology Group</i>

List of Abbreviations (cont...)

<i>Abb.</i>	<i>Full term</i>
<i>TCC.....</i>	<i>Transitional Cell Carcinoma</i>
<i>TRUS.....</i>	<i>Trans Rectal Ultrasound</i>
<i>UCSF.....</i>	<i>University of California San Francisco</i>
<i>USPSTF</i>	<i>US Preventive Services Task Force</i>
<i>Vs</i>	<i>Versus</i>

ABSTRACT

Background: Prostate cancer is the second most common cancer in men and the seventh leading cause of male cancer death worldwide. It is a highly heterogeneous disease with great variability in its clinical course. Treatment options vary depending on age, stage, and grade of cancer, as well as other medical conditions.

Aim of study: In this retrospective study we aimed to provide clinico-epidemiological characteristics of prostate cancer and to present different treatment modalities with respect to OS, DFS and PFS.

Patients and Methods: Male patients with localized or metastatic prostate cancer presented to Ain Shams University Hospitals in the period from January 2010, to December 2015. In our study, we reviewed medical records of 101 patients including demographic data and clinic-pathological factors were reported, including age, sex, performance status (ECOG), co-morbidities, personal habits, tumor characteristics, surgery, radical treatment, metastatic treatment, treatment response and survival rates were collected.

Results: Our population under study had a median age of 69 years (range: 42-85), majority of our patients (94%) had good ECOG performance status (≤ 2), (45.5%) of the patients were presented to us with metastatic disease, most common symptoms at presentation were prostatism in 72.8% of patients and bony aches in 18.8%. The mean Gleason score among studied population was mean 7.37. 44.6% of the patients were metastatic at time of presentation. Median overall survival in studied population was 31 months, median PFS of the studied group was 17 months and the median DFS 29 months.

Conclusion: We provide an overview of patients with prostate cancer in a single tertiary institution in Cairo and it was found that lack of patient awareness in most patients leads to their late presentation at time of diagnosis.

Key word: Prostate cancer; Diagnosis; Enzalutamide; Salvage; Egypt.

INTRODUCTION

Prostate cancer is the second most common cancer in males. It was estimated that about 1.1 million men worldwide of prostate cancer were diagnosed in 2012, with estimated age-standardized incidence rates were 30.7 per 100,000, which represented 15% of the malignances diagnosed in men, with almost 70% of the cases (759,000) occurring in more developed regions. The estimated number of deaths was almost 307,000 and the estimated age-standardized mortality rates were 7.8 per 100,000 (*Globocan, 2012*).

A man's life time risk of developing prostate cancer is one out of seven (*Siegel et al., 2015*). The global burden of prostate cancer is expected to raise 1.7 million new cases and 499,000 deaths by 2030 due to growth and aging of the worldwide population (*Ferlay et al., 2010*).

Prostate cancer is the fifth leading cause of death from cancer in men (6.6% of the total men deaths). Because PSA testing has a much greater effect on incidence than on mortality, there is less variation in mortality rates worldwide (ten-fold from approximately 3 to 30 per 100,000) than is observed for incidence, with the number of deaths from prostate cancer larger in less developed than in more developed regions (165,000 and 142,000, respectively) (*Globocan, 2012*).

Prostate cancer patients have a good survival rate if the cancer is diagnosed at an early stage (*Leitzmann et al., 2012*). Improvements in detection and treatment recently may result in a better outlook for men now being diagnosed with prostate cancer. Five years relative survival rate for local and regional stage are almost 100% and for distant stage is 28% (*American Cancer Society, 2015*).

In Egypt, age-standardized incidence rates were 7.8 per 100,000 and mortality rates were 5.1 per 100,000 (*Globocan, 2012*).

Prostate cancer is a disease of elderly men. Almost 6 cases in 10 are diagnosed at the age of 65 years or later. It is rare before the age of 40, but the chance of developing prostate cancer rises rapidly after the age of 50. The average age at the time of diagnosed is almost 66 years (*American Cancer Society, 2015*). The age especially 55 years and above had almost 17-fold higher risk of developing prostate cancer as compared to age less than 55 years (*Bashir et al., 2014*).

African-Americans have the highest rates of prostate cancer in the world (223.0 per 100,000 men). The incidence among African-Americans is about 60% higher than whites (139.9 per 100,000 men). The incidence rate for all races is 147.8 per 100,000 men. Moreover, for the period 2007 to 2011, the mortality rate for African Americans was 2.4 times higher than whites (*Howlader et al., 2014*).